{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:50:35Z","timestamp":1794336635709,"version":"4.9.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-53384-1","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T13:02:05Z","timestamp":1729861325000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials"],"prefix":"10.1038","volume":"15","author":[{"given":"Jonathan I.","family":"Silverberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rosmarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6510-399X","authenticated-orcid":false,"given":"Raj","family":"Chovatiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Schleicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8452-667X","authenticated-orcid":false,"given":"Lisa","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohail","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie","family":"Fanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danni","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Tagliaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Nirula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kotzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2707-1709","authenticated-orcid":false,"given":"Jonathan","family":"Zalevsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"key":"53384_CR1","doi-asserted-by":"publisher","first-page":"eabl9165","DOI":"10.1126\/sciimmunol.abl9165","volume":"7","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Classification of human chronic inflammatory skin disease based on single-cell immune profiling. Sci. Immunol. 7, eabl9165 (2022).","journal-title":"Sci. Immunol."},{"key":"53384_CR2","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/jid.2014.530","volume":"135","author":"FJ Dalgard","year":"2015","unstructured":"Dalgard, F. J. et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J. Invest. Dermatol. 135, 984\u2013991 (2015).","journal-title":"J. Invest. Dermatol."},{"key":"53384_CR3","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/jdv.12154","volume":"28","author":"A Langenbruch","year":"2014","unstructured":"Langenbruch, A. et al. Quality of health care of atopic eczema in Germany: results of the national health care study AtopicHealth. J. Eur. Acad. Dermatol. Venereol. 28, 719\u2013726 (2014).","journal-title":"Acad. Dermatol. Venereol."},{"key":"53384_CR4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/978-3-319-64804-0_8","volume":"1027","author":"AS Adamson","year":"2017","unstructured":"Adamson, A. S. The Economics Burden of Atopic Dermatitis. Adv. Exp. Med. Biol. 1027, 79\u201392 (2017).","journal-title":"Adv. Exp. Med. Biol."},{"key":"53384_CR5","doi-asserted-by":"publisher","first-page":"592","DOI":"10.7861\/clinmedicine.9-6-592","volume":"9","author":"AY Finlay","year":"2009","unstructured":"Finlay, A. Y. The burden of skin disease: quality of life, economic aspects and social issues. Clin. Med. (Lond.) 9, 592\u2013594 (2009).","journal-title":"Clin. Med. (Lond.)"},{"key":"53384_CR6","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.3390\/ijms23094898","volume":"23","author":"WY Chen","year":"2022","unstructured":"Chen, W. Y. et al. Annoying Psoriasis and Atopic Dermatitis: A Narrative Review. Int. J. Mol. Sci. 23, 4898 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"53384_CR7","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.jaci.2022.02.015","volume":"149","author":"B Roediger","year":"2022","unstructured":"Roediger, B. & Schlapbach, C. T cells in the skin: Lymphoma and inflammatory skin disease. J. Allergy Clin. Immunol. 149, 1172\u20131184 (2022).","journal-title":"J. Allergy Clin. Immunol."},{"key":"53384_CR8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/JID.2015.362","volume":"136","author":"M Carretero","year":"2016","unstructured":"Carretero, M. et al. Differential Features between Chronic Skin Inflammatory Diseases Revealed in Skin-Humanized Psoriasis and Atopic Dermatitis Mouse Models. J. Inv. Dermatol. 136, 136\u2013145 (2016).","journal-title":"J. Inv. Dermatol."},{"key":"53384_CR9","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","volume":"159","author":"AS Paller","year":"2023","unstructured":"Paller, A. S. et al. Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial. JAMA Dermatol 159, 596\u2013605 (2023).","journal-title":"JAMA Dermatol"},{"key":"53384_CR10","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson, E. L. et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N. Engl. J. Med. 375, 2335\u20132348 (2016).","journal-title":"N. Engl. J. Med."},{"key":"53384_CR11","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.2147\/CCID.S364640","volume":"15","author":"A Ruggiero","year":"2022","unstructured":"Ruggiero, A., Picone, V., Martora, F., Fabbrocini, G. & Megna, M. Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence. Clin. Cosmet. Investig. Dermatol. 15, 1649\u20131658 (2022).","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"53384_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1358\/dot.2023.59.3.3419557","volume":"59","author":"T Simopoulou","year":"2023","unstructured":"Simopoulou, T., Tsiogkas, S. G., Zafiriou, E. & Bogdanos, D. P. Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis. Drugs Today (Barc.) 59, 135\u2013167 (2023).","journal-title":"Drugs Today (Barc.)"},{"key":"53384_CR13","doi-asserted-by":"publisher","first-page":"134","DOI":"10.12788\/j.sder.2018.039","volume":"37","author":"M Chima","year":"2018","unstructured":"Chima, M. & Lebwohl, M. TNF inhibitors for psoriasis. Semin. Cutan. Med. Surg. 37, 134\u2013142 (2018).","journal-title":"Semin. Cutan. Med. Surg."},{"key":"53384_CR14","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40257-020-00548-6","volume":"21","author":"S Ferreira","year":"2020","unstructured":"Ferreira, S., Guttman-Yassky, E. & Torres, T. Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib. Am. J. Clin. Dermatol. 21, 783\u2013798 (2020).","journal-title":"Am. J. Clin. Dermatol."},{"key":"53384_CR15","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.2147\/CCID.S433367","volume":"16","author":"M Megna","year":"2023","unstructured":"Megna, M. et al. JAK Inhibitors in Psoriatic Disease. Clin. Cosmet. Investig. Dermatol. 16, 3129\u20133145 (2023).","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"53384_CR16","doi-asserted-by":"publisher","first-page":"875492","DOI":"10.3389\/fmed.2022.875492","volume":"9","author":"H Ujiie","year":"2022","unstructured":"Ujiie, H. et al. Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases. Front. Med. 9, 875492 (2022).","journal-title":"Front. Med."},{"key":"53384_CR17","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.3389\/fimmu.2019.03100","volume":"10","author":"D Shevyrev","year":"2020","unstructured":"Shevyrev, D. & Tereshchenko, V. Treg Heterogeneity, Function, and Homeostasis. Front. Immunol. 10, 3100 (2020).","journal-title":"Front. Immunol."},{"key":"53384_CR18","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","volume":"133","author":"S Sakaguchi","year":"2008","unstructured":"Sakaguchi, S., Yamaguchi, T., Nomura, T. & Ono, M. Regulatory T cells and immune tolerance. Cell 133, 775\u2013787 (2008).","journal-title":"Cell"},{"key":"53384_CR19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/bjd.19380","volume":"184","author":"L Nussbaum","year":"2021","unstructured":"Nussbaum, L., Chen, Y. L. & Ogg, G. S. Role of regulatory T cells in psoriasis pathogenesis and treatment. Br. J. Dermatol. 184, 14\u201324 (2021).","journal-title":"Br. J. Dermatol."},{"key":"53384_CR20","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nrd.2018.148","volume":"17","author":"A Sharabi","year":"2018","unstructured":"Sharabi, A. et al. Regulatory T cells in the treatment of disease. Nat. Rev. Drug Discov. 17, 823\u2013844 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"53384_CR21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.5114\/ada.2017.71105","volume":"34","author":"B Nedoszytko","year":"2017","unstructured":"Nedoszytko, B. et al. The role of regulatory T cells and genes involved in their differentiation in pathogenesis of selected inflammatory and neoplastic skin diseases. Part II: The Treg role in skin diseases pathogenesis. Postepy. Dermatol. Alergol. 34, 405\u2013417 (2017).","journal-title":"Postepy. Dermatol. Alergol."},{"key":"53384_CR22","doi-asserted-by":"publisher","first-page":"eaat1482","DOI":"10.1126\/sciimmunol.aat1482","volume":"3","author":"AK Abbas","year":"2018","unstructured":"Abbas, A. K., Trotta, E., D, R. S., Marson, A. & Bluestone, J. A. Revisiting IL-2: Biology and therapeutic prospects. Sci. Immunol. 3, eaat1482 (2018).","journal-title":"Sci. Immunol."},{"key":"53384_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","volume":"78","author":"M Rosenzwajg","year":"2019","unstructured":"Rosenzwajg, M. et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann. Rheum. Dis. 78, 209\u2013217 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"53384_CR24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","volume":"79","author":"J He","year":"2020","unstructured":"He, J. et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 79, 141\u2013149 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"53384_CR25","doi-asserted-by":"publisher","first-page":"179ra143","DOI":"10.1126\/scitranslmed.3005265","volume":"5","author":"K Matsuoka","year":"2013","unstructured":"Matsuoka, K. et al. Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease. Sci. Transl. Med. 5, 179ra143\u2013179ra143 (2013).","journal-title":"Sci. Transl. Med."},{"key":"53384_CR26","first-page":"2009","volume":"50","author":"MW Konrad","year":"1990","unstructured":"Konrad, M. W. et al. Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Res. 50, 2009\u20132017 (1990).","journal-title":"Cancer Res"},{"key":"53384_CR27","doi-asserted-by":"publisher","first-page":"100103","DOI":"10.1016\/j.jtauto.2021.100103","volume":"4","author":"N Dixit","year":"2021","unstructured":"Dixit, N. et al. NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases. J. Transl. Autoimmun. 4, 100103 (2021).","journal-title":"J. Transl. Autoimmun."},{"key":"53384_CR28","doi-asserted-by":"publisher","first-page":"100152","DOI":"10.1016\/j.jtauto.2022.100152","volume":"5","author":"C Fanton","year":"2022","unstructured":"Fanton, C. et al. Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus. J. Transl. Autoimmun. 5, 100152 (2022).","journal-title":"J. Transl. Autoimmun."},{"key":"53384_CR29","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/bjd.19457","volume":"184","author":"JI Silverberg","year":"2021","unstructured":"Silverberg, J. I. et al. What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study. Br. J. Dermatol. 184, 888\u2013895 (2021).","journal-title":"Br. J. Dermatol."},{"key":"53384_CR30","doi-asserted-by":"publisher","first-page":"D687","DOI":"10.1093\/nar\/gkab1028","volume":"50","author":"M Gillespie","year":"2022","unstructured":"Gillespie, M. et al. The reactome pathway knowledgebase 2022. Nucleic Acids Res. 50, D687\u2013d692 (2022).","journal-title":"Nucleic Acids Res"},{"key":"53384_CR31","doi-asserted-by":"publisher","first-page":"104539","DOI":"10.1016\/j.ebiom.2023.104539","volume":"90","author":"ME Raeber","year":"2023","unstructured":"Raeber, M. E., Sahin, D., Karakus, U. & Boyman, O. A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases. EBioMedicine 90, 104539 (2023).","journal-title":"EBioMedicine"},{"key":"53384_CR32","doi-asserted-by":"publisher","first-page":"585819","DOI":"10.3389\/fimmu.2020.585819","volume":"11","author":"F Bayati","year":"2021","unstructured":"Bayati, F. et al. The Therapeutic Potential of Regulatory T Cells: Challenges and Opportunities. Front. Immunol. 11, 585819 (2021).","journal-title":"Front. Immunol."},{"key":"53384_CR33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40425-014-0026-0","volume":"2","author":"JP Dutcher","year":"2014","unstructured":"Dutcher, J. P. et al. High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014. J. Immunother. Cancer 2, 26 (2014).","journal-title":"J. Immunother. Cancer"},{"key":"53384_CR34","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt, A. et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 389, 2287\u20132303 (2017).","journal-title":"Lancet"},{"key":"53384_CR35","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s40257-023-00792-6","volume":"24","author":"L Stein Gold","year":"2023","unstructured":"Stein Gold, L. et al. Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials. Am. J. Clin. Dermatol. 24, 595\u2013607 (2023).","journal-title":"Am. J. Clin. Dermatol."},{"key":"53384_CR36","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/bjd.20810","volume":"186","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg, A. et al. Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials. Br. J. Dermatol. 186, 453\u2013465 (2022).","journal-title":"Br. J. Dermatol."},{"key":"53384_CR37","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s10753-023-01883-6","volume":"46","author":"Z Qiao","year":"2023","unstructured":"Qiao, Z. et al. Low-dose Interleukin-2 For Psoriasis Therapy Based on the Regulation of Th17\/Treg Cell Balance in Peripheral Blood. Inflammation 46, 2359\u20132373 (2023).","journal-title":"Inflammation"},{"key":"53384_CR38","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/cmi.2015.10","volume":"12","author":"Z Li","year":"2015","unstructured":"Li, Z., Li, D., Tsun, A. & Li, B. FOXP3+ regulatory T cells and their functional regulation. Cell. Mol. Immunol. 12, 558\u2013565 (2015).","journal-title":"Cell. Mol. Immunol."},{"key":"53384_CR39","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/j.1365-2133.2012.10814.x","volume":"166","author":"C Luci","year":"2012","unstructured":"Luci, C. et al. Peripheral natural killer cells exhibit qualitative and quantitative changes in patients with psoriasis and atopic dermatitis. Br. J. Dermatol. 166, 789\u2013796 (2012).","journal-title":"Br. J. Dermatol."},{"key":"53384_CR40","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jaci.2020.04.052","volume":"146","author":"K Kabashima","year":"2020","unstructured":"Kabashima, K. & Weidinger, S. NK cells as a possible new player in atopic dermatitis. J. Allergy Clin. Immunol. 146, 276\u2013277 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"53384_CR41","doi-asserted-by":"publisher","first-page":"eaay1005","DOI":"10.1126\/scitranslmed.aay1005","volume":"12","author":"MR Mack","year":"2020","unstructured":"Mack, M. R. et al. Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis. Sci. Transl. Med. 12, eaay1005 (2020).","journal-title":"Sci. Transl. Med."},{"key":"53384_CR42","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jaci.2022.02.001","volume":"150","author":"L M\u00f6bus","year":"2022","unstructured":"M\u00f6bus, L. et al. Blood transcriptome profiling identifies 2 candidate endotypes of atopic dermatitis. J. Allergy Clin. Immunol. 150, 385\u2013395 (2022).","journal-title":"J. Allergy Clin. Immunol."},{"key":"53384_CR43","doi-asserted-by":"publisher","first-page":"kyad012","DOI":"10.1093\/discim\/kyad012","volume":"2","author":"M Lee","year":"2023","unstructured":"Lee, M. et al. CD56bright natural killer cells preferentially kill proliferating CD4+ T cells. Discov. Immunol. 2, kyad012 (2023).","journal-title":"Discov. Immunol."},{"key":"53384_CR44","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.4049\/jimmunol.1502570","volume":"196","author":"T Michel","year":"2016","unstructured":"Michel, T. et al. Human CD56bright NK Cells: An Update. J. Immunol. 196, 2923\u20132931 (2016).","journal-title":"J. Immunol."},{"key":"53384_CR45","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/S0140-6736(22)02037-2","volume":"401","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky, E. et al. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. Lancet 401, 204\u2013214 (2023).","journal-title":"Lancet"},{"key":"53384_CR46","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jdermsci.2006.08.004","volume":"44","author":"S Hashimoto","year":"2006","unstructured":"Hashimoto, S. et al. Macrophage-derived chemokine (MDC)\/CCL22 produced by monocyte derived dendritic cells reflects the disease activity in patients with atopic dermatitis. J. Dermatol. Sci. 44, 93\u201399 (2006).","journal-title":"J. Dermatol. Sci."},{"key":"53384_CR47","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1111\/all.15949","volume":"79","author":"R Bissonnette","year":"2024","unstructured":"Bissonnette, R. et al. Clinical and molecular effects of oral CCR4 antagonist RPT193 in atopic dermatitis: A Phase 1 study. Allergy 79, 924\u2013936 (2024).","journal-title":"Allergy"},{"key":"53384_CR48","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1159\/000508515","volume":"181","author":"H Karlen","year":"2020","unstructured":"Karlen, H., Yousefi, S., Simon, H.-U. & Simon, D. IL-15 Expression Pattern in Atopic Dermatitis. Int. Arch. Allergy Immunol. 181, 417\u2013421 (2020).","journal-title":"Int. Arch. Allergy Immunol."},{"key":"53384_CR49","first-page":"168","volume":"46","author":"S Chong","year":"2016","unstructured":"Chong, S., Lan, H., Zeng, K. & Zhao, X. Serum Fractalkine (CX3CL1) Concentration Correlates with Clinical Severity in Pediatric Atopic Dermatitis Patients. Ann. Clin. Lab. Sci. 46, 168\u2013173 (2016).","journal-title":"Ann. Clin. Lab. Sci."},{"key":"53384_CR50","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","volume":"147","author":"Y Renert-Yuval","year":"2021","unstructured":"Renert-Yuval, Y. et al. Biomarkers in atopic dermatitis\u2014a review on behalf of the International Eczema Council. J. Allergy Clin. Immunol. 147, 1174\u20131190.e1171 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"53384_CR51","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/jid.2011.371","volume":"132","author":"C G\u00fcnther","year":"2012","unstructured":"G\u00fcnther, C., Carballido-Perrig, N., Kaesler, S., Carballido, J. M. & Biedermann, T. CXCL16 and CXCR6 are upregulated in psoriasis and mediate cutaneous recruitment of human CD8+ T cells. J. Invest. Dermatol. 132, 626\u2013634 (2012).","journal-title":"J. Invest. Dermatol."},{"key":"53384_CR52","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41423-019-0291-4","volume":"17","author":"L Chen","year":"2020","unstructured":"Chen, L. & Shen, Z. Tissue-resident memory T cells and their biological characteristics in the recurrence of inflammatory skin disorders. Cell. Mol. Immunol. 17, 64\u201375 (2020).","journal-title":"Cell. Mol. Immunol."},{"key":"53384_CR53","doi-asserted-by":"publisher","first-page":"618897","DOI":"10.3389\/fimmu.2020.618897","volume":"11","author":"Y Tokura","year":"2021","unstructured":"Tokura, Y., Phadungsaksawasdi, P., Kurihara, K., Fujiyama, T. & Honda, T. Pathophysiology of Skin Resident Memory T Cells. Front. Immunol. 11, 618897 (2021).","journal-title":"Front. Immunol."},{"key":"53384_CR54","doi-asserted-by":"crossref","unstructured":"Fanton, C. & Zalevsky, J. Recent patents in allergy and immunology: The interleukin-2 receptor pathway agonist rezpegaldesleukin (REZPEG) for the rescue of regulatory T cells in chronic inflammatory and autoimmune disease. Allergy 79, 2565\u20132566 (2024).","DOI":"10.1111\/all.16271"},{"key":"53384_CR55","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.anai.2020.07.026","volume":"126","author":"JI Silverberg","year":"2021","unstructured":"Silverberg, J. I. et al. Real-world persistence with dupilumab among adults with atopic dermatitis. Ann. Allergy Asthma Immunol. 126, 40\u201345 (2021).","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"53384_CR56","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","volume":"156","author":"M Worm","year":"2020","unstructured":"Worm, M. et al. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol 156, 131\u2013143 (2020).","journal-title":"JAMA Dermatol"},{"key":"53384_CR57","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s13555-022-00764-4","volume":"12","author":"MJ Gooderham","year":"2022","unstructured":"Gooderham, M. J. et al. Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial. Dermatol. Ther. (Heidelb.) 12, 2077\u20132085 (2022).","journal-title":"Dermatol. Ther. (Heidelb.)"},{"key":"53384_CR58","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","volume":"86","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt, A. et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J. Am. Acad. Dermatol. 86, 104\u2013112 (2022).","journal-title":"J. Am. Acad. Dermatol."},{"key":"53384_CR59","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.intimp.2009.07.003","volume":"9","author":"L Engstrom","year":"2009","unstructured":"Engstrom, L. et al. Characterization of a murine keyhole limpet hemocyanin (KLH)-delayed-type hypersensitivity (DTH) model: role for p38 kinase. Int. Immunopharmacol. 9, 1218\u20131227 (2009).","journal-title":"Int. Immunopharmacol."},{"key":"53384_CR60","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","volume":"70","author":"LF Eichenfield","year":"2014","unstructured":"Eichenfield, L. F. et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J. Am. Acad. Dermatol. 70, 338\u2013351 (2014).","journal-title":"J. Am. Acad. Dermatol."},{"key":"53384_CR61","first-page":"154","volume":"15","author":"JF Fowler Jr.","year":"2016","unstructured":"Fowler, J. F. Jr., Hebert, A. A. & Sugarman, J. DFD-01, a Novel Medium Potency Betamethasone Dipropionate 0.05% Emollient Spray, Demonstrates Similar Efficacy to Augmented Betamethasone Dipropionate 0.05% Lotion for the Treatment of Moderate Plaque Psoriasis. J. Drugs Dermatol. 15, 154\u2013162 (2016).","journal-title":"J. Drugs Dermatol."},{"key":"53384_CR62","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/bjd.14464","volume":"175","author":"AB Kimball","year":"2016","unstructured":"Kimball, A. B. et al. Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis. Br. J. Dermatol. 175, 157\u2013162 (2016).","journal-title":"Br. J. Dermatol."},{"key":"53384_CR63","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/ijd.12645","volume":"54","author":"AN Naegeli","year":"2015","unstructured":"Naegeli, A. N., Flood, E., Tucker, J., Devlen, J. & Edson-Heredia, E. The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis. Int. J. Dermatol. 54, 715\u2013722 (2015).","journal-title":"Int. J. Dermatol."},{"key":"53384_CR64","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/DER.0000000000000895","volume":"33","author":"JM Hanifin","year":"2022","unstructured":"Hanifin, J. M. et al. The Eczema Area and Severity Index-A Practical Guide. Dermatitis 33, 187\u2013192 (2022).","journal-title":"Dermatitis"},{"key":"53384_CR65","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/bjd.12403","volume":"169","author":"JJ Scarisbrick","year":"2013","unstructured":"Scarisbrick, J. J. & Morris, S. How big is your hand and should you use it to score skin in cutaneous T-cell lymphoma? Br. J. Dermatol. 169, 260\u2013265 (2013).","journal-title":"Br. J. Dermatol."},{"key":"53384_CR66","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","volume":"21","author":"T Bieber","year":"2022","unstructured":"Bieber, T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat. Rev. Drug Discov. 21, 21\u201340 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"53384_CR67","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000365390","volume":"230","author":"MK Basra","year":"2015","unstructured":"Basra, M. K., Salek, M. S., Camilleri, L., Sturkey, R. & Finlay, A. Y. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology 230, 27\u201333 (2015).","journal-title":"Dermatology"},{"key":"53384_CR68","first-page":"50","volume":"147","author":"FA Khilji","year":"2002","unstructured":"Khilji, F. A., Gonzalez, M. & Finlay, A. Clinical meaning of change in Dermatology Life Quality Index scores. Br. J. Dermatol. 147, 50 (2002).","journal-title":"Br. J. Dermatol."},{"key":"53384_CR69","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/bjd.12590","volume":"169","author":"CR Charman","year":"2013","unstructured":"Charman, C. R., Venn, A. J., Ravenscroft, J. C. & Williams, H. C. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br. J. Dermatol. 169, 1326\u20131332 (2013).","journal-title":"Br. J. Dermatol."},{"key":"53384_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v082.i13","volume":"82","author":"A Kuznetsova","year":"2017","unstructured":"Kuznetsova, A., Brockhoff, P. B. & Christensen, R. H. B. lmerTest Package: Tests in Linear Mixed Effects Models. J. Stat. Soft. 82, 1\u201326 (2017).","journal-title":"J. Stat. Soft."},{"key":"53384_CR71","unstructured":"Lenth, R. V. emmeans: Estimated marginal means, aka least-squares means. https:\/\/rvlenth.github.io\/emmeans\/ (2023)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53384-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53384-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53384-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T14:02:58Z","timestamp":1729864978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53384-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["53384"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-53384-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3705537\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]},"assertion":[{"value":"16 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JS has received honoraria as a consultant and\/or advisory board member for Abbvie, Aldena, Amgen, AObiome, Apollo, Arcutis, Arena, Asana, Aslan, Attovia, BioMX, Biosion, Bodewell, Boehringer-Ingelheim, Bristol Meyers Squibb, Cara, Castle Biosciences, Celgene, Connect Biopharma, Corevitas, Dermavant, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Invea, Kiniksa, Leo Pharma, My-Or Diagnostics, Nektar, Novartis, Optum, Pfizer, RAPT, Recludix, Regeneron, Sanofi-Genzyme, Shaperon, TARGET-RWE, Union, UpToDate; speaker for Abbvie, Eli Lilly, Leo Pharma, Pfizer, Regeneron, Sanofi-Genzyme; stock\/stock options for Connect, Verdant; institution received grants from Galderma, Incyte, Pfizer DR has consulted, spoken for, or conducted trials for the following companies: AbbVie, Abcuro, AltruBio, Amgen, Arena, Boehringer-Ingelheim, Bristol Meyers Squibb, Celgene, Concert, CSL Behring, Dermavant, Dermira, Galderma, Incyte, Janssen, Kyowa Kirin, Lilly, Merck, Nektar, Novartis, Pfizer, RAPT, Regeneron, Recludix, Revolo Biotherapeutics, Sanofi, Sun Pharmaceuticals, UCB, VielaBio, Zura Bio. RC has served as an advisor, consultant, speaker, and\/or investigator for AbbVie, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis, Argenx, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, Eli Lilly and Company, FIDE, Formation Bio, Galderma, Genentech, GSK, Incyte, LEO Pharma, L\u2019Or\u00e9al, Nektar Therapeutics, Novartis, Opsidio, Pfizer Inc., RAPT, Regeneron, Sanofi, Sitryx, Takeda, TRexBio, and UCB. TB has been a speaker and\/or consultant and\/or Investigator for AbbVie, Affibody, Almirall, Amagma, AnaptysBio, AOBiom, Apogee, Arena, Aristea, Artax, Asana Biosciences, ASLAN pharma, Astria, Attovia, Bayer Health, Biofilm control, BioVerSys, B\u00f6hringer-Ingelheim, Bristol-Myers Squibb, Connect Pharma, Daichi-Sanyko, Dermavant, DICE Therapeutics, Domain Therapeutics, DS Pharma, EQRx, Galderma, Galapagos, Glenmark, GSK, Incyte, Innovaderm, IQVIA, Janssen, Kirin, Kymab, LEO, LG Chem, Lilly, L\u00b4Or\u00e9al, MSD, Medac, Micreos, Nektar, Novartis, Numab, OM-Pharma, Overtone, Pfizer, Pierre Fabre, Q32bio, RAPT, Samsung Bioepis, Sanofi\/Regeneron, TIRmed, UCB, Union Therapeutics, UPStream Bio, YUHAN. He is founder and chairman of the board of the non-profit biotech Davos Biosciences within the international K\u00fchne-Foundation. SS has received research funding from Eli Lilly and Company, Amgen, Galderma, HighLight Therapeutics, Encube, Cara Therapeutics, Vyne, Novan, AstraZeneca. Honoria for Nektar. Consulting\/Advisory Role for Nektar. LB has been a consultant and\/or investigator for Abbvie, Allakos, Amgen, Arcutis, Arena Pharmaceuticals, AstraZeneca, Astria Therapeutics, Evelo Biosciences, Escient Pharma, Galderma, Incyte, Invea Therapeutics, Janssen, LEO Pharma, Merck, Nektar Therapeutics, Novartis, Numab Therapeutics, Pfizer, Rapt Therapeutics, Regeneron Pharmaceuticals Inc., Ribon Therapeutics, Sanofi-Aventis\/Genzyme, Sitryx Therapeutics, Stealth BioTherapeutics, Trevi Therapeutics, UCB Pharma, Union therapeutics, and Xencor. MG has been an investigator, speaker and\/or advisor for: AbbVie, Acelyrin, Amgen, Akros, Arcutis, Aristea, AnaptysBio, Apogee, Bausch Health, BMS, Boehringer Ingelheim, Cara, Dermira, Dermavant, Eli Lilly, Galderma, GSK, Incyte, InMagene, JAMP Pharma, Janssen, Kyowa Kirin, LEO Pharma, L\u2019Oreal, MedImmune, Meiji, Moonlake, Nektar, Nimbus, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, Tarsus, Takeda, UCB, Union, Ventyx and Vyne. SC, CF, DY, YL, BK, TM, MT, and JZ are employees and stockholders at Nektar Therapeutics. MT also has a leadership role and is a shareholder in Enzo Biochem and RayzeBio. CS and AN are shareholders at Eli Lilly and Company. AN is a shareholder at Recludix Pharma. JL is a stockholder in Eli Lilly and Company.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9230"}}